<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193163</url>
  </required_header>
  <id_info>
    <org_study_id>2018-37</org_study_id>
    <nct_id>NCT04193163</nct_id>
  </id_info>
  <brief_title>Observational Study Conducted on Patients Receiving the ESOP 2 Stem to Confirm Security and Performance of the Device</brief_title>
  <acronym>ESOP2</acronym>
  <official_title>Prospective Observational Clinical Study Conducted Over a 10-year Period on Patients Who Received the ESOP 2 Stem to Restore Joint Function, in Order to Confirm Security and Performance of the Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FH Orthopedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FH Orthopedics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a post-market clinical follow-up conducted in order to collect long-term data
      on security and performance of the ESOP 2 stem, which is intended to be implanted in case of
      total hip replacement, when used in real life conditions according to the instructions for
      use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the security of the ESOP 2 stem by
      calculating the survival rate up to 10 years of follow-up.

      The secondary objectives are to evaluate the security and performance of the device by
      assessing radiological data, gathering complications and evaluating functional score and
      quality of life score up to 10 years of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate</measure>
    <time_frame>10 years post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographies evaluation</measure>
    <time_frame>immediate post-op, 3 months post-op, 1 year post-op, 5 years post-op, 10 years post-op</time_frame>
    <description>Radiological results such as stability, osteointegration will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>per-op, 3 months post-op, 1 year post-op, 5 years post-op, 10 years post-op</time_frame>
    <description>All complications will be gathered during intervention and up to 10 years postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes such as pain, mobility</measure>
    <time_frame>pre-op, 3 months post-op, 1 year post-op, 5 years post-op, 10 years post-op</time_frame>
    <description>Functional outcomes will be determined by the Harris Hip score. This score ranges from 0 to 100, where, the higher the score, the better the patient outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation</measure>
    <time_frame>pre-op, 3 months post-op, 1 year post-op, 5 years post-op, 10 years post-op</time_frame>
    <description>Quality of life will be determined by the OXFORD-12 score. This score ranges from 12 points to 60 points, where, the higher the score, the better the patient outcome.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Hip Disease</condition>
  <condition>Hip Fractures</condition>
  <arm_group>
    <arm_group_label>Patients receiving ESOP 2 stem</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hip prosthesis - ESOP 2 cementless femoral stem</intervention_name>
    <description>ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.</description>
    <arm_group_label>Patients receiving ESOP 2 stem</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from participating hospitals will be enrolled as part of their clinical routine
        care.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject implanted with ESOP 2 stem in one of the following indication according to the
             instructions for use: hip disorders; femoral neck fracture

          -  Subject who received an information form and is willing to participate in the study

        Exclusion Criteria:

          -  Contraindications described in the instructions for use

          -  Usual surgical contraindications

          -  Subject who is not able to express his/her non-opposition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Project Leader</last_name>
    <phone>0033389818827</phone>
    <email>n.mathias@groupe-fh.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Tivoli Ducos</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nouvelle Clinique Bel-Air</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Pasteur</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Raymond POINCARE</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH de Haguenau</name>
      <address>
        <city>Haguenau</city>
        <zip>67504</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique du Val d'Ouest</name>
      <address>
        <city>Écully</city>
        <zip>69130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthroplasty</keyword>
  <keyword>Hip replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

